Bristol immune drug shows strong effect in melanoma study
September 29, 2014 at 03:00 AM EDT
MADRID, Sept 29 (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option.